Lisa Peoples
Nurse Practitioner · Birmingham, ALNPI 1912180761
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 25.3% of the total. Reporting peaked in 2023 at $5,932 and has fallen 71.7% since, to $1,682 in 2025. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 539 payments — averaging $32.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- Sanofi$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Johnson & Johnson$963
- plus $3K from 27 others
What the payments were for
- Consulting fees$3,14318%
- Speaking & faculty fees$2,40014%
- Travel & lodging$2,23813%
- Food & beverage$9,64955%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 27 | $4,432 |
| Sanofi | 25 | $3,687 |
| Takeda Pharmaceuticals U.S.A., Inc. | 59 | $1,874 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 108 | $1,776 |
| AbbVie | 113 | $1,699 |
| Johnson & Johnson | 54 | $963 |
| Gilead | 32 | $602 |
| Ardelyx, Inc. | 24 | $455 |
| Pfizer | 18 | $260 |
| Ironwood Pharmaceuticals, Inc | 14 | $246 |
| E.r. Squibb & Sons, L.L.C. | 2 | $220 |
| Bristol Myers Squibb | 13 | $206 |
| Lilly USA, LLC | 4 | $175 |
| Madrigal Pharmaceuticals | 5 | $120 |
| QOL Medical, LLC | 5 | $115 |
| Evoke Pharma, Inc. | 5 | $109 |
| Braintree Laboratories, Inc. | 6 | $87 |
| Ipsen Biopharmaceuticals, Inc | 4 | $84 |
| Nestle Healthcare Nutrition Inc. | 5 | $74 |
| Merck | 2 | $40 |
| Exact Sciences | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Enterra Medical, Inc. | 1 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Organon | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $17 |
| Intra-sana Laboratories | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,486 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 82 | $54,980 |
| CreonLipase/Protease/Amylase | 19 | $40,102 |
| TrulancePlecanatide | 16 | $13,259 |
| Budesonide DrBudesonide | 56 | $11,670 |
| Dexlansoprazole DrDexlansoprazole | 50 | $10,900 |
| Mesalamine ErMesalamine | 37 | $9,053 |
| Ursodiol | 51 | $7,275 |
| Colestipol Hcl | 82 | $5,254 |
| Budesonide EcBudesonide | 16 | $3,644 |
| Pantoprazole Sodium | 413 | $3,469 |
| Methscopolamine Bromide | 17 | $3,156 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 16 | $2,591 |
| Sucralfate | 110 | $2,454 |
| Famotidine | 181 | $2,240 |
| Esomeprazole Magnesium | 37 | $2,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,699 | $95,083101 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,776 | $13,25916 claims |
| Braintree Laboratories, Inc.Sutab | $87 | $2,59116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Birmingham
- Ginger McDanielBirmingham$27K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Samantha WeaverBirmingham$17K
- Logan GilmoreBirmingham$13K
- Jennifer CothronBirmingham$13K
- Chelsea KelleyBirmingham$13K
- Vanessa HillBirmingham$11K
- Heather BuffingtonBirmingham$10K
- Jeanny RileyBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.